Dyslipidemia

Biotech provides nonhuman research materials to develop HDL therapy

Published in Health and Medicine Week, November 22nd, 2004

RxGen, Inc. has completed a research contract with Lipid Sciences, Inc (LIPD). The contract has provided research materials derived from a nonhuman primate model of diet-induced dyslipidemia to advance development of Lipid Sciences' proprietary delipidation technology.

Lipid Sciences' patented HDL therapy technology, designed for the treatment of cardiovascular disease, has now entered a safety and efficacy study, with significant support from RxGen's preclinical research capabilities.

RxGen's preclinical research capabilities allow business partners to test and validate experimental therapeutic products in human primate models of human...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2004-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry